AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03425513 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Description: Participants will be asked to fill in a questionnaire regarding demographic characteristics, known viral hepatitis status and risk factors for HBV infection.
Study NCT02869503 — intervention group
Intervention type: OTHER
Intervention: Data collection
Study NCT02470416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD
Description: Cases and controls will have a standard VCE procedure at our institution.
Study NCT00835159 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivastigmine Patch
Description: Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
Study NCT00835159 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Patch
Description: A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
Study NCT02215031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 44370
Study NCT02215031 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03221699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Formula with ZnO
Description: Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
Study NCT03221699 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Formula without ZnO
Description: Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
Study NCT05428293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A1: Ibuprofen/Acetaminophen Fixed dose combination oral suspension (Laboratorios Silanes S.A. de C.V.)
Description: Formula : 100 mg/ 125 mg /5mL Pharmaceutical Form: Oral suspension Dosage: 5mL (100 mg/125mg) Administration way: oral
Study NCT05428293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A2: Ibuprofen (Advil®, Pfizer S.A. de C.V.)
Description: Pharmaceutical Form: oral suspension Formula: 2 g/100 mL Dosage: 5 mL(100 mg of Ibuprofen) Administration way: oral
Study NCT05428293 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: A3: Acetaminophen (Tylenol®, from Janssen-Cilag, S.A. de C.V.)
Description: Pharmaceutical Form: oral suspension Formula: 3.2 g/100 mL Dosage: 3.9 mL (125 mg) Administration way: oral
Study NCT02996695 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01629342 — intervention group
Intervention type: BEHAVIORAL
Intervention: Standardized activities
Description: All patients do each of the following standardized activities over a course of 2 days:~* treadmill walking (5 minutes, 1 and 2km/h)~* staircase walking (1 floor, normal pace)~* cycling with fixed load (5 minutes)~* standing up from sitting position and sitting down again (x5)~* standing up from supine position~* turning from left to right and back while lying in bed~* raising outstretched arm 90° (x5, standing position)~* eating (5 minutes, sitting position)~* drinking a glass of water~* sleeping (6 hours)
Study NCT01808248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBV
Description: Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
Study NCT04445701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176
Description: Humanized monoclonal antibody (mAb) targeting CD47
Study NCT04445701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Dex
Description: Humanized mAb targeting CD47 plus dexamethasone
Study NCT04445701 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AO-176 + Dex + Bort
Description: Humanized mAb targeting CD47 plus dexamethasone plus bortezomib
Study NCT01745081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20% mannitol bolus administration
Study NCT03701399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: troriluzole
Description: 200 mg by mouth
Study NCT03480061 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine Hydrochloride Group
Description: Dexmedetomidine will be initiated prior to transfer to the CVICU with loading dose of 1 ug kg-1 over approximately 20 minutes. This will be followed by an infusion at 0.1-1.0 ug kg-1h-1 in CVICU for up to 24 hours from the time DEX infusion started or until the patient is ready for discharge from the CVICU (whichever is earlier).
Study NCT03157635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crovalimab
Description: Crovalimab will be administered as per schedule described in individual arm.
Study NCT03701399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 200 mg by mouth
Study NCT02738632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan/Amlodipine+Hydrochlorothiazide
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD
Study NCT02738632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Telmisartan/Amlodipine
Description: Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD~Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD
Study NCT02738632 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo for Hydrochlorothiazide
Study NCT04040244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exhaled Breath Collection
Description: Exhaled breath condensate (EBC) and exhaled breath volatiles (EBV) samples will be obtained over 5-10 minutes using a one-time use R-tube apparatus.
Study NCT04040244 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood sample
Description: Blood samples collected simultaneously with routine standard of care blood draws.
Study NCT03564028 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: energy conservation technique
Description: During the session of stair climbing, patients will perform a break at least of 5 seconds every 3 steps.
Study NCT03564028 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control session
Description: Patients will realize one session of stair climbing at their own pace
Study NCT00437320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Cream 160 mg/g
Description: Participants were treated with topical administration of Metvix cream.
Study NCT00437320 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metvix Vehicle Group
Description: Participants were treated with topical administration of Metvix Vehicle cream.
Study NCT02987842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TruScan Neurofeedback
Description: Neurofeedback and quantitative EEG system
Study NCT02987842 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: TruScan Neurofeedback
Description: Neurofeedback and quantitative EEG system
Study NCT01938573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Given IV
Study NCT01745081 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hypertonic saline 3% bolus administration
Study NCT00519103 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Study NCT01324544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine IV
Description: Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
Study NCT03854409 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Description: Injection.
Study NCT00003387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Study NCT00003387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: chemotherapy
Study NCT01938573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT01938573 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Given PO
Study NCT01938573 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cystectomy
Description: Undergo cystectomy when appropriate
Study NCT01649609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Reduction of standard immunosuppression - The standard of care immunosuppression treatment commonly used for renal transplant patients
Study NCT01649609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate acid
Description: Myfortic or CellCept - The standard of care immunosuppression treatment most commonly used for renal transplant patients
Study NCT01649609 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: mTOR Substitution - Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
Study NCT02899845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: postural task
Study NCT02899845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: postural task
Study NCT02899845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk task
Study NCT02899845 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: walk task
Study NCT01522807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
Study NCT01522807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
Study NCT01522807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
Study NCT01522807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
Study NCT01522807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-05190457
Description: 100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
Study NCT03248336 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: office-based vergence/accommodative therapy
Description: one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
Study NCT02482493 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sigma PFC
Description: patients will receive either an all polyethylene tibial component or a metal- backed component
Study NCT00967486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with routine shount
Study NCT01408797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: donor specific transfusion
Description: before transplantation,200mL of donor whole blood will be transfused to the recipient
Study NCT01408797 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MMF, Bortezomib
Description: MMF and Bortezomib will be administered after donor specific transfusion
Study NCT01408797 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: drugs added according to the immuno condition of the recipients
Description: drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
Study NCT00003387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Study NCT00003387 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT02005939 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Pomegranate extract
Description: All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
Study NCT01619956 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SLA dental implants
Description: Dental implant with surface modification.
Study NCT01619956 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SLA dental implants
Description: Dental implant with surface modification.
Study NCT01619956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation
Description: After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre.
Study NCT01619956 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Osteotome sinus floor elevation
Description: After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre.
Study NCT03157635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered as per schedule described in Part 1 placebo arm.
Study NCT00967486 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Carotid endarterectomy with selective shunt
Study NCT02811614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Evacuation
Description: Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
Study NCT02811614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic Aspiration
Description: Using image guidance to aspirate hematoma.
Study NCT02811614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Craniotomy
Description: Craniotomy with a big bone flap to evacuate intracerebral hematoma.
Study NCT02759484 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Enhanced Education
Description: The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
Study NCT02759484 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic Based Enhanced Education
Description: The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
Study NCT02175784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ipragliflozin
Description: oral
Study NCT02175784 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: oral
Study NCT03886662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LB-100
Description: Phase Ib: Two escalating doses of LB-100 in two separate cohorts will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.~Phase 2: Safe dose of LB-100 as determined from phase Ib will be administered intravenously on days 1, 3 and 5 of a 21-day cycle over 120 minutes.
Study NCT02602392 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lungtropolis
Description: A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
Study NCT02602392 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Asthma educational booklet
Description: Text-based asthma education booklet for parents and children in PDF format
Study NCT02302534 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI
Study NCT02518204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPT
Description: Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
Study NCT02518204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: NP
Description: Conventional in-person Neuropsychological Assessments (NP)~Subtests from:~* HRB: Halstead-Reitan Battery~* MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia~* WAIS-IV: Weschler Adult Intelligence Scale - IV
Study NCT00965809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tetrahydrocannabinol
Description: Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
Study NCT00965809 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
Study NCT01922557 — intervention group
Intervention type: DEVICE
Intervention: NICOM
Description: NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
Study NCT03159117 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06688992
Description: (PF-06688992) will be administered on Day 1 of each 21-day cycle per the Dose Preparation and Administration Instructions (DAI) located in the Investigational Product Manual (Appendix 4Appendix 3) as an IV infusion over approximately 60 minutes. A cycle is defined as the time from Day 1 dose to the next Day 1 dose. If there are no treatment delays, a cycle will be 21 days. Each patient may receive PF-06688992 until disease progression, unacceptable toxicity, withdrawal of consent, or study termination
Study NCT04081324 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally
Study NCT04081324 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally
Study NCT01400815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: X-22 Smoking Cessation Product
Description: The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
Study NCT01400815 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Active Control Cigarettes
Description: The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.~Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period.
Study NCT01192373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Metabolic substrate modulation
Description: for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
Study NCT01192373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: metabolic substrate modulation
Description: low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
Study NCT04247776 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Prehab
Description: Exercise: functional exercises, walking, Fitbit goals Nutrition: handout, supplements (protein, vitamins, minerals) Stress reduction: deep breathing
Study NCT04247776 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ERAS
Description: Enhanced Recovery After Surgery guidelines are applied.
Study NCT04247776 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ERAS
Description: Enhanced Recovery After Surgery guidelines are applied.
Study NCT01619956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone grafting
Description: the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
Study NCT04405908 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: SCB-2019
Description: SCB-2019 intramuscular vaccinations at 3 µg up to 30 µg twice (on Day 1 and Day 22).
Study NCT04247776 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit is worn to monitor step counts.
Study NCT04247776 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit
Description: Fitbit is worn to monitor step counts.